{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-000691","form_type":"8-K","ticker":"PTHS","cik":"0001919246","company_name":"Pelthos Therapeutics Inc.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.205753+00:00","generated_at":"2026-06-04T01:09:47.759354+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Chromocell updates on $6.6M IPO, pipeline progress, and liability reduction","bullets":["Closed IPO Feb 21, 2024, gross proceeds ~$6.6M; all pre-IPO debt and Series A preferred converted.","Removed ~$2.7M in liabilities via Series C preferred issuance and CEO compensation deferral.","Lead candidate CC8464 completed Phase I (no euphoria, 4% rash incidence); slow dose escalation planned before Phase II.","New eye pain program CT2000 launched; Dr. Simon Chandler hired; animal toxicity studies expected H2 2024.","10-K delayed due to IPO workload; expects filing within permitted 15-day extension."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-000691","json":"https://secwatch.observer/filing/0001753926-24-000691.json","markdown":"https://secwatch.observer/filing/0001753926-24-000691.md","text":"https://secwatch.observer/filing/0001753926-24-000691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000691/0001753926-24-000691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1919246/000175392624000691/g084169_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:09:47.759354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}